Connection

JIANJUN GAO to Female

This is a "connection" page, showing publications JIANJUN GAO has written about Female.
Connection Strength

0.173
  1. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.020
  2. Towards effective adjuvant treatment for urothelial cancer. Lancet Oncol. 2015 Jan; 16(1):9-10.
    View in: PubMed
    Score: 0.014
  3. The proteasome regulates bacterial CpG DNA-induced signaling pathways in murine macrophages. Shock. 2010 Oct; 34(4):390-401.
    View in: PubMed
    Score: 0.010
  4. Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. Cancer Res Commun. 2024 Oct 01; 4(10):2621-2637.
    View in: PubMed
    Score: 0.007
  5. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist. 2024 Jul 05; 29(7):589-595.
    View in: PubMed
    Score: 0.007
  6. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist. 2024 May 03; 29(5):392-399.
    View in: PubMed
    Score: 0.007
  7. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol. 2024 06; 148:1-6.
    View in: PubMed
    Score: 0.007
  8. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.
    View in: PubMed
    Score: 0.006
  9. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
    View in: PubMed
    Score: 0.006
  10. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
    View in: PubMed
    Score: 0.006
  11. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998.
    View in: PubMed
    Score: 0.005
  12. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24.
    View in: PubMed
    Score: 0.005
  13. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.005
  14. Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.
    View in: PubMed
    Score: 0.005
  15. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021 07 15; 149(2):387-393.
    View in: PubMed
    Score: 0.005
  16. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin. BJU Int. 2021 07; 128(1):65-71.
    View in: PubMed
    Score: 0.005
  17. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
    View in: PubMed
    Score: 0.005
  18. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.
    View in: PubMed
    Score: 0.005
  19. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol. 1999 Oct 15; 163(8):4095-9.
    View in: PubMed
    Score: 0.005
  20. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.
    View in: PubMed
    Score: 0.005
  21. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019 10 20; 37(30):2738-2745.
    View in: PubMed
    Score: 0.005
  22. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
    View in: PubMed
    Score: 0.005
  23. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflamm Bowel Dis. 2019 01 10; 25(2):385-393.
    View in: PubMed
    Score: 0.005
  24. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.
    View in: PubMed
    Score: 0.004
  25. Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene. J Immunol. 1998 Nov 01; 161(9):4803-10.
    View in: PubMed
    Score: 0.004
  26. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.004
  27. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
    View in: PubMed
    Score: 0.004
  28. Anomalous role of tumor necrosis factor alpha in experimental enterococcal infection. Infect Immun. 2002 Dec; 70(12):6628-37.
    View in: PubMed
    Score: 0.001
  29. A candidate interferon-gamma activated site (GAS element) in the HLA-G promoter does not bind nuclear proteins. Hum Immunol. 1999 Nov; 60(11):1113-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.